News | January 23, 2024
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
